Xenon Pharmaceuticals Inc’s filing revealed that its PRESIDENT & CEO MORTIMER IAN unloaded Company’s shares for reported $0.9 million on Jan 24 ’25. In the deal valued at $40.20 per share,22,468 shares were sold. As a result of this transaction, MORTIMER IAN now holds 31,302 shares worth roughly $0.97 million.
Then, MORTIMER IAN sold 16,315 shares, generating $660,806 in total proceeds. Upon selling the shares at $40.50, the PRESIDENT & CEO now owns 31,302 shares.
Before that, MORTIMER IAN sold 16,217 shares. Xenon Pharmaceuticals Inc shares valued at $649,977 were divested by the PRESIDENT & CEO at a price of $40.08 per share. As a result of the transaction, MORTIMER IAN now holds 31,302 shares, worth roughly $0.97 million.
Chardan Capital Markets initiated its Xenon Pharmaceuticals Inc [XENE] rating to a Buy in a research note published on May 07, 2025; the price target was $55. A number of analysts have revised their coverage, including Deutsche Bank’s analysts, who began to cover the stock in mid February with a ‘”a Buy”‘ rating. H.C. Wainwright started covering the stock on October 01, 2024. It rated XENE as “a Buy”.
Price Performance Review of XENE
On Monday, Xenon Pharmaceuticals Inc [NASDAQ:XENE] saw its stock jump 2.18% to $30.95. Over the last five days, the stock has lost -13.67%. Xenon Pharmaceuticals Inc shares have fallen nearly -21.05% since the year began. Nevertheless, the stocks have fallen -23.49% over the past one year.
How much short interest is there in Xenon Pharmaceuticals Inc?
A steep rise in short interest was recorded in Xenon Pharmaceuticals Inc stocks on 2025-04-30, dropping by -0.36 million shares to a total of 3.58 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 3.95 million shares. There was a decline of -10.12%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 04, 2024 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $62 price target.
